Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)

Contributed by: Business Wire

Logo

Tags

Oncology

FDA

Health

Neurology

Clinical Trials

Pharmaceutical

Corticorelin

More Like This

Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved

Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-01

Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track

Curatis Increases Revenue Growth Guidance for 2026

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3

Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues

Curatis discloses Corticorelin as active substance of C-PTBE-01